13 slides from Starpharma's conference presentation, Oct 28, 2021
Slide 1: Enhancing drug delivery: DEP dendrimer platform
Enhancing drug delivery DEP® dendrimer platform Tony Eglezos VP Business Development PODD #PODD2021
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward- looking terminology such as “promising”, “plans”, “articipated’, “wil”, “project’, "beleve", “forecast”, “expected, “estimated,
Slide 3: Starpharma's DEP strategy
Starpharma’s DEP® strategy : “To leverage our proprietary dendrimer platform to build high value products and partnerships that address significant unmet need” PODD #PODD2021 3
Slide 4: Partnering creates significant value and optionality
DEP® partnering creates significant value and optionality Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs, creating multiple potential revenue streams and significant IP leverage PODD #PODD2021
Slide 6: DEP drug delivery platform enhances therapeutic and commercial value of drugs
Starpharma’s DEP® drug delivery platform enhances the therapeutic and commercial value of drugs PODD #PODD2021 6
Slide 7: Technology platform with multiple commercial opportunities in oncology and beyond
DEP® is a technology platform with multiple commercial opportunities in oncology and beyond PODD #PODD2021 7
Slide 8: Internal oncology programs
DEP® internal oncology programs Multiple clinical-stage assets with high commercial value potential PODD #PODD2021 8
Slide 9: Drugs are ideal candidates for combination therapy
DEP® drugs are also ideal candidates for combination therapy- conventional, targeted and Immuno-Oncology approaches PODD #PODD2021 9
Slide 10: Targeted DEP conjugates provide additional flexibility
Targeted DEP® conjugates provide additional flexibility PODD #PODD2021 10
Slide 11: ADC / Radiotheranostic platform
DEP® ADC / Radiotheranostic platform Flexibility in targeting approach – Flexibility in payload - Enhanced performance PODD These experiments were conducted in either a human ovarian cancer #PODD2021 (SKOV-3) or human prostate cancer (DU-145) mouse xenograft model 11
Slide 12: Platform – significant optionality, therapeutic and commercial benefits